Ovid Therapeutics Inc.: 10-Q filed 2018-11-08
What Ovid Therapeutics Inc. reported in its quarterly report filed 2018-11-08 (fiscal Q3 2018): 31 published measures, 83 facts as tagged in accession 0001564590-18-028299.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2018-11-08
- Fiscal period
- fiscal Q3 2018
- Accession
- 0001564590-18-028299 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Ovid Therapeutics Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 60,393,974 | USD | |
| At 2017-12-31 | 89,457,603 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 49,971,069 | USD | |
| At 2017-12-31 | 83,436,503 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 30,513,180 | USD | |
| At 2017-12-31 | 87,125,600 | USD | |
| At 2017-09-30 | 96,042,773 | USD | |
| At 2016-12-31 | 51,939,661 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | -12,961,783 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -39,079,678 | USD | 273 |
| 2017-07-01 to 2017-09-30 | -9,358,606 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -53,845,790 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | -34,592,870 | USD | 273 |
| 2017-01-01 to 2017-09-30 | -22,463,987 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | 39,492 | USD | 273 |
| 2017-01-01 to 2017-09-30 | 31,105 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | 286,138 | USD | 273 |
| 2017-01-01 to 2017-09-30 | 66,676,192 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | -22,305,688 | USD | 273 |
| 2017-01-01 to 2017-09-30 | -109,093 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | -139,795,346 | USD | |
| At 2017-12-31 | -100,715,668 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 68,154 | USD | |
| At 2017-12-31 | 51,775 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | 5,332,781 | USD | 273 |
| 2017-01-01 to 2017-09-30 | 4,987,088 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | -13,175,775 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -39,805,387 | USD | 273 |
| 2017-07-01 to 2017-09-30 | -9,409,112 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -53,959,500 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 55,254,234 | USD | |
| At 2017-12-31 | 88,588,048 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 10,422,905 | USD | |
| At 2017-12-31 | 6,021,100 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 4,593,501 | USD | |
| At 2017-12-31 | 2,025,766 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 406,078 | USD | |
| At 2017-12-31 | 124,194 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | 13,175,775 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 39,805,387 | USD | 273 |
| 2017-07-01 to 2017-09-30 | 9,409,112 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 53,959,500 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | 8,544,547 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 25,168,446 | USD | 273 |
| 2017-07-01 to 2017-09-30 | 5,899,482 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 43,258,833 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 24,654,114 | shares | |
| At 2017-12-31 | 24,606,256 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | -4,675 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 76,466 | USD | |
| At 2017-12-31 | 50,915 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 406,078 | USD | |
| At 2017-12-31 | 124,194 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 5,829,404 | USD | |
| At 2017-12-31 | 3,995,334 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-09-30 | 2,746,680 | USD | |
| At 2017-12-31 | 1,462,448 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | -12,950,436 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -39,084,353 | USD | 273 |
| 2017-07-01 to 2017-09-30 | -9,358,606 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -53,845,790 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | -12,961,783 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -39,079,678 | USD | 273 |
| 2017-07-01 to 2017-09-30 | -9,358,606 | USD | 92 |
| 2017-01-01 to 2017-09-30 | -53,845,790 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | 4,631,228 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 14,636,941 | USD | 273 |
| 2017-07-01 to 2017-09-30 | 3,509,630 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 10,700,667 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | 6,746 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 25,551 | USD | 273 |
| 2017-07-01 to 2017-09-30 | 7,171 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 19,155 | USD | 273 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | 86,441 | USD | 273 |
| 2017-01-01 to 2017-09-30 | 58,590 | USD | 273 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | 24,615 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 60,890 | USD | 273 |
| 2017-07-01 to 2017-09-30 | 13,864 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 39,436 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-07-01 to 2018-09-30 | 213,992 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 725,709 | USD | 273 |
| 2017-07-01 to 2017-09-30 | 50,506 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 113,710 | USD | 273 |
Inspect the source
- Entity
- Ovid Therapeutics Inc. / CIK 0001636651
- Captured
- 2026-09-21T17:21:21.098Z
- SEC response SHA-256
b4de1e66c6e8e0453b1f8d4fc2f1dafe6798859207cf5a42629d88fe4c5e512a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001636651.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))